| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Active Biotech AB > News item |
Active Biotech: daily TASQ treatment cuts PSA rate in prostate cancer
By Lisa Kerner
Charlotte, N.C., Sept. 20 - Active Biotech AB said an interim analysis of its ongoing TASQ phase 1 study shows a treatment effect for all evaluated prostate cancer patients.
The analysis was made after 10 patients completed four months of daily 0.5 mg TASQ treatment. All 10 patients had a reduced rate of PSA (prostate-specific antigen) increase, with nine out of 10 patients having a decrease of more than 50%.
A total of 24 patients with hormone refractory prostate cancer are in the phase 1 study.
The Lund, Sweden, pharmaceutical company plans to begin phase 2/3 studies in 2007.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.